ArticleBMC medical imaging2026
Radiomics using contrast-enhanced T1-weighted imaging and clinical features for predicting response to EGFR-TKIs in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo construct and validate a model based on clinical characteristics and magnetic resonance imaging (MRI) radiomics to predict 1-year efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BMs).
methodsThis study retrospectively analyzed data from 338 patients with EGFR-mutant NSCLC BMs from three centers, including MRI, clinical and pathological data, and radiological features. Based on the selected significant radiomic features from intratumoral regions extracted from CE-T1WI, while exploring the value of features in 3/5/8 mm peritumoral regions, seven commonly used machine learning algorithms were compared to select the optimal one for model construction, and the best algorithm was selected for model construction. In the model predicting 1-year therapeutic efficacy, clinical, radiomic, and combined models were constructed separately. The model performance was evaluated using receiver operating characteristic curves.
resultsThe final development cohort comprised 285 patients from Center 1, while the external validation set included 57 patients from Centers 2 and 3. In the model predicting 1-year EGFR-TKIs efficacy, the random forest algorithm, which showed the best application, was used to construct the model. Compared with the radiomic and clinical models, the combined model exhibited superior area under the curve performance in the test set (0.756 vs. 0.644 vs. 0.668). In the external validation set, the combined model achieved an area under the curve of 0.743 (95% CI: 0.604-0.881).
conclusionCompared to single clinical or radiomic models, the combined model was more effective in predicting the 1-year efficacy of EGFR-TKIs in patients with NSCLC BMs with EGFR mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.